| New Immunosuppressive Drugs Used in Renal Transplantation | Özkan GÜNGÖR, Bülent TOKGÖZ, İrem PEMBEGÜL, Alper ALP | 239–245 |
| The Use of Carnitine in Hemodialysis Patients | Hilal YILDIRAN, Büşra ATABİLEN | 246–253 |
| Gut Microbiota and Role of Dietary Fiber in Chronic Kidney Disease | Ebru MELEKOĞLU, F. Gülhan SAMUR | 254–260 |
| Association Between Vascular Access Type and Visceral and Peripheral Body Fat, Nutritional and Inflammatory Parameters in Incident Hemodialysis Patients | Gültekin GENÇTOY, Cevahir HABERAL, Tonguç SABA, Tayfun BİRTAY | 261–270 |
| Investigation of the Interventions of the Patients After Kidney Transplantation to Protect Themselves at Home | Eda DOLGUN, Meryem YAVUZ VAN GIERSBERGEN, Nebile ÖZDEMİR, Yasemin AYDINLI, Gülsün ORDU | 271–274 |
| Epidemiology and Clinical and Radiographic Characteristics of Pneumonia in Kidney Transplant Recipients; 24-Year Experience | Halis AKALIN, Alparslan ERSOY, Oğuzhan Sıtkı DİZDAR | 275–284 |
| Electrolyte Abnormalities in Patients with Type 2 Diabetes Mellitus | Oğuzhan ÖZCAN, Müge ÖZSAN, Mustafa YAPRAK, Faruk TURGUT, Esra KİRİKTİR | 285–289 |
| Association of Presence and Quantity of C4d with the Severity of Kidney Injury in Primary Membranous Nephropathy | Mehtat ÜNLÜ, Caner ÇAVDAR, Taner ÇAMSARI, Sülen SARIOĞLU, Serkan YILDIZ, Esra GÖKÇE | 290–297 |
| Comparison of Different Dialysis Modalities in End-Stage Renal Disease Patients with Acute Dialysis Requirement | Bülent TOKGÖZ, Murat Hayri SİPAHİOĞLU, Cevat YAZICI, Eray EROĞLU, Aydın ÜNAL, Oktay OYMAK, İsmail KOÇYİĞİT, Muhammed DOĞAN, İmran DOĞAN | 298–304 |
| Experience with Treatment of Retroperitoneal Fibrosis: Collaboration of Urology and Nephrology Departments for 26 years in Marmara University | Mehmet KOÇ, Yılören TANIDIR, Cem AKBAL, Ferruh ŞİMŞEK, Mahir Bülent ÖZGEN, Çağrı Akın ŞEKERCİ | 305–310 |
| Evaluation of Hemodialysis Patients in Terms of Activities of Daily Living, Disability, Depression and Comorbidity | Gülay TURGAY, Emre TUTAL, Siren SEZER |